RUMORED BUZZ ON LINSITINIB MECHANISM OF ACTION

The LIDS trial satisfied its Key endpoint with statistical importance for the 150mg BID dose. Linsitinib On this trial validated the protection profile found in the prior oncology scientific studies and importantly demonstrated a good basic safety profile on critical adverse events (AEs) of interest to the IGF-1R goal for example Listening to impai